ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 1990, p. 2263-2266
Vol. 34, No. 11
0066-4804/90/112263-04$02.00/0 Copyright C) 1990, American Society for Microbiology
In Vitro Activity of Sparfloxacin (CI-978; AT-4140) against Clinical Isolates from Cancer Patients ROLSTON,* HIEU NGUYEN, MARK MESSER, BARBARA LEBLANC, DAI H. HO, AND GERALD P. BODEY Section of Infectious Diseases, Department of Medical Specialties, The University of Texas
KENNETH V.
I.
M. D. Anderson Cancer Center, Houston, Texas 77030 Received 2 April 1990/Accepted 10 August 1990 The in vitro activity of sparfloxacin, a new quinolone, was compared with those of ciprofloxacin and fleroxacin against gram-positive and gram-negative bacteria, >90% of which were isolated from blood culture specimens of cancer patients. Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Kiebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting >90% of these isolates at a concentration of 0.5 ,ig/ml) and moderately active against Pseudomonas species, other Proteus species, and Citrobacterfreundii. Sparfloxacin inhibited >90% of staphylococci (including methicillin-resistant and coagulase-negative strains) at a concentration of 0.12 ,ig/ml and >90% of streptococci (including Streptococcus pneumoniae) at a concentration of 1.0 ,ug/mI. It was also active against Bacillus cereus, Enterococcus species, and Corynebacterium jeikeium, organisms that have become fairly common in cancer patients.
the basis of an MIC of
Vol. 34, No. 11
0066-4804/90/112263-04$02.00/0 Copyright C) 1990, American Society for Microbiology
In Vitro Activity of Sparfloxacin (CI-978; AT-4140) against Clinical Isolates from Cancer Patients ROLSTON,* HIEU NGUYEN, MARK MESSER, BARBARA LEBLANC, DAI H. HO, AND GERALD P. BODEY Section of Infectious Diseases, Department of Medical Specialties, The University of Texas
KENNETH V.
I.
M. D. Anderson Cancer Center, Houston, Texas 77030 Received 2 April 1990/Accepted 10 August 1990 The in vitro activity of sparfloxacin, a new quinolone, was compared with those of ciprofloxacin and fleroxacin against gram-positive and gram-negative bacteria, >90% of which were isolated from blood culture specimens of cancer patients. Sparfloxacin was extremely active against Acinetobacter species, Aeromonas hydrophila, Citrobacter diversus, Enterobacter species, Escherichia coli, Kiebsiella species, Proteus vulgaris, and Serratia marcescens (inhibiting >90% of these isolates at a concentration of 0.5 ,ig/ml) and moderately active against Pseudomonas species, other Proteus species, and Citrobacterfreundii. Sparfloxacin inhibited >90% of staphylococci (including methicillin-resistant and coagulase-negative strains) at a concentration of 0.12 ,ig/ml and >90% of streptococci (including Streptococcus pneumoniae) at a concentration of 1.0 ,ug/mI. It was also active against Bacillus cereus, Enterococcus species, and Corynebacterium jeikeium, organisms that have become fairly common in cancer patients.
the basis of an MIC of
